Kadmon Corp LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile
April 2017
38
About the Report
About the Report
Kadmon Corp LLC (Kadmon) is a biopharmaceutical company that offers products and related services for the management and treatment of hepatitis C. The company also develops therapies for metabolic and serious diseases. Its products include ribavirin, USP Tablets, ribavirin capsules, phentermine and topiramate extended-release capsules and trientine hydrochloride. Kadmon offers products in the therapeutic areas of oncology, infectious diseases, immunology, and neurodegenerative disease. The company's discovery platforms include metabolomics, chromics, monoclonal antibodies, synthetic biology and gene regulation. It undertakes identification and evaluation of investigational compounds, which show the potential to improve patient outcomes. Kadmon is headquartered in New York, the US.
Kadmon Corp LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description-A brief description of the company's operations.
Key Employees-A list of the key executives of the company.
Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors-A list of the key competitors of the company.
Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Kadmon Corp LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kadmon Corp LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Kadmon Acquires Rights To Salirasib From Concordia Pharma 12
Venture Financing 13
Kadmon Raises USD5.7 Million in Venture Financing 13
Kadmon Raises US$4.7 Million In Venture Financing 13
Kadmon Pharma Secures US$40 Million In Venture Financing 14
Partnerships 15
Kadmon Amends Distribution Agreement with Camber Pharma 15
Kadmon Enters into R&D Agreement with NIDCR 15
EffRx Pharma Enters An Agreement With Kadmon 16
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 17
Kadmon Pharma Forms Joint Venture With Nano Terra 18
Licensing Agreements 19
Nantong Jinghua Pharma Enters into Licensing Agreement with Kadmon 19
Kadmon Enters into Licensing Agreement with VIVUS for Qsymia 20
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 21
Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 22
Kadmon Enters Into Licensing Agreement With Chiromics For Chemical Compounds Library 23
Dyax Enters Into Licensing Agreement With Kadmon 24
Equity Offering 25
Kadmon Plans to Raise Funds through Public Offering of Shares 25
Kadmon Prices IPO for USD75 Million 26
Kadmon Raises USD11 Million in Private Placement of Units 27
Kadmon Raises USD5.5 Million in Private Placement of Units 28
Kadmon Raises USD10 Million in Private Placement of Units 28
Kadmon Raises USD35 Million in Private Placement of Units 29
Kadmon Raises USD15 Million in Private Placement of Units 30
Asset Transactions 30
AbbVie Acquires Rights to Ribasphere from Kadmon 30
Acquisition 31
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 31
Kadmon Corp LLC-Key Competitors 33
Key Employees 34
Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Sep 07, 2016: Kadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016 36
Clinical Trials 37
Apr 14, 2016: Kadmon to Present Preclinical Data Demonstrating that its Novel Immuno-Oncology Compound Achieves Long-Lasting and Persistent Antitumor Immunity 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Figure
List of Figures
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
List of Table
List of Tables
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Key Facts 1
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kadmon Corp LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kadmon Corp LLC, Deals By Therapy Area, 2011 to YTD 2017 9
Kadmon Corp LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kadmon Acquires Rights To Salirasib From Concordia Pharma 12
Kadmon Raises USD5.7 Million in Venture Financing 13
Kadmon Raises US$4.7 Million In Venture Financing 13
Kadmon Pharma Secures US$40 Million In Venture Financing 14
Kadmon Amends Distribution Agreement with Camber Pharma 15
Kadmon Enters into R&D Agreement with NIDCR 15
EffRx Pharma Enters An Agreement With Kadmon 16
Kadmon Pharma Enters Into Co-Promotion Agreement With Valeant Pharma For Syprine Capsules 17
Kadmon Pharma Forms Joint Venture With Nano Terra 18
Nantong Jinghua Pharma Enters into Licensing Agreement with Kadmon 19
Kadmon Enters into Licensing Agreement with VIVUS for Qsymia 20
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 21
Dyax Enters Into Licensing Agreement With Kadmon For Oncology Drug 22
Kadmon Enters Into Licensing Agreement With Chiromics For Chemical Compounds Library 23
Dyax Enters Into Licensing Agreement With Kadmon 24
Kadmon Plans to Raise Funds through Public Offering of Shares 25
Kadmon Prices IPO for USD75 Million 26
Kadmon Raises USD11 Million in Private Placement of Units 27
Kadmon Raises USD5.5 Million in Private Placement of Units 28
Kadmon Raises USD10 Million in Private Placement of Units 28
Kadmon Raises USD35 Million in Private Placement of Units 29
Kadmon Raises USD15 Million in Private Placement of Units 30
AbbVie Acquires Rights to Ribasphere from Kadmon 30
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 31
Kadmon Corp LLC, Key Competitors 33
Kadmon Corp LLC, Key Employees 34
Kadmon Corp LLC, Other Locations 35
Kadmon Corp LLC, Subsidiaries 35
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.